Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
- 1 September 2011
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 6 (9), 1474-1480
- https://doi.org/10.1097/jto.0b013e3182208fc2
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant KinasesJournal of Clinical Oncology, 2010
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRThe New England Journal of Medicine, 2010
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 2009
- The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRASCancer, 2009
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung CancersJournal of Thoracic Oncology, 2008
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007